Last €103.53 EUR
Change Today +2.38 / 2.35%
Volume 371.0
CG3 On Other Exchanges
As of 11:15 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

celgene corp (CG3) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/3/14 - €126.75
52 Week Low
06/6/13 - €84.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELGENE CORP (CG3)

celgene corp (CG3) Related Businessweek News

View More BusinessWeek News

celgene corp (CG3) Details

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company’s commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The company’s pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders; and strategic alliance with Forma Therapeutics. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

5,100 Employees
Last Reported Date: 02/13/14
Founded in 1980

celgene corp (CG3) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $1.2M
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $729.2K
Chief Operations Officer, Executive Vice Pres...
Total Annual Compensation: $625.0K
Executive Vice President and President of Res...
Total Annual Compensation: $625.0K
Chief Commercial Officer, Global Head of Hema...
Total Annual Compensation: $641.7K
Compensation as of Fiscal Year 2012.

celgene corp (CG3) Key Developments

Mylan Pharmaceuticals Sues Celgene over Cancer Drugs

Mylan Pharmaceuticals Inc. on April 3, 2014 sued Celgene Corp. in federal court in New Jersey, claiming the company had monopolized sales of two prescription medications by keeping lower-priced generics out of the market. Celgene's two drugs are Thalomid and Revlimid, which are prescribed to treat multiple myeloma, a form of cancer. Thalomid is a brand name for thalidomide, which also has been used to treat Hansen's disease, more commonly known as leprosy. Because of the drugs' potency and side effects that include birth defects, Calgene has unfairly used federally mandated restrictions on distribution of the drugs to keep generic competitors out of the market.

FORMA Therapeutics and Celgene Corporation Announce Novel and Expansive Multi-Year Strategic Alliance

FORMA Therapeutics announced a second strategic collaboration and option agreement with Celgene Corporation. This new collaboration will enable FORMA to extend its unique capabilities across broad areas of chemistry and biology. Upon signing the agreement, FORMA received an upfront cash payment of $225 million, and the parties entered into a collaboration with a term of 3 1/2 years. In addition to the 3 1/2 year collaboration, Celgene has the option to enter into up to two additional collaborations with terms of two years each for additional payments totaling approximately $375 million.

Celgene Corporation Announces Approval of OTEZLA by the U.S. Food and Drug Administration for the Treatment of Adults with Active Psoriatic Arthritis

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA (apremilast), the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active psoriatic arthritis. A chronic disorder, psoriatic arthritis is characterized by pain, stiffness, swelling and tenderness of the joints, inflammation of specific ligaments and tendons, and a decrease in physical functioning. OTEZLA is the only FDA-approved oral treatment for psoriatic arthritis. OTEZLA treatment with or without (+/-) concomitant DMARDs, compared with placebo +/- concomitant DMARDs, resulted in greater improvement in the signs and symptoms of psoriatic arthritis, as demonstrated by the proportion of patients with an ACR 20 response at week 16. In PALACE-1, 38% of patients treated with OTEZLA(R) (apremilast) 30 mg twice daily achieved an ACR 20 response at week 16 versus 19% of patients on placebo. Consistent results were observed in PALACE-2 and PALACE-3. Improvement in ACR 50 and ACR 70 responses were observed at week 16 across the three studies. A characteristic of psoriatic arthritis is tenderness and swelling in and around the joints. At week 16, patients treated with OTEZLA achieved a reduction in tender and swollen joint counts compared with placebo. OTEZLA treatment resulted in improvement for each of the seven ACR components measured, compared with placebo, at week 16. Improvements were also seen in disease-related physical functioning. Treatment with OTEZLA resulted in improvement in dactylitis (inflammation of fingers and toes) and enthesitis (inflammation at sites where tendons or ligaments insert into bone) in patients with these pre-existing symptoms. Enthesitis and dactylitis are specific disease manifestations related to psoriatic arthritis. In OTEZLA clinical trials, the majority of the most common adverse reactions occurred within the first two weeks of treatment and tended to resolve over time with continued dosing. Adverse reactions reported in at least two% of patients on OTEZLA 30 mg twice daily and at least one% greater than that observed in patients on placebo for up to 16 weeks were diarrhea, nausea, headache, upper respiratory tract infection, vomiting, nasopharyngitis, and upper abdominal pain. The proportion of patients who discontinued treatment due to any adverse reaction was 4.6% for patients taking OTEZLA 30 mg twice daily and 1.2% for patients taking placebo. The most common adverse reactions leading to discontinuation among patients treated up to 16 weeks with OTEZLA 30 mg twice daily were nausea (1.8 percent), diarrhea (1.8 percent) and headache (1.2 percent). OTEZLA is contraindicated for use in patients with a known severe allergic reaction to OTEZLA or other components in OTEZLA. Across the three PALACE studies, 1.0% (10/998) of patients treated with OTEZLA reported depression or depressed mood compared with 0.8% (4/495) treated with placebo; 0.3% (4/1441) of patients treated with OTEZLA discontinued treatment due to depression or depressed mood compared with none among placebo-treated patients. In the PALACE studies, 10% of patients taking OTEZLA, compared with 3.3% of patients taking placebo, reported weight loss of five to ten percent. It is recommended that patients taking OTEZLA have their weight checked regularly. OTEZLA(R) (apremilast) is expected to be available in the U.S. in March 2014 and will be dispensed through a comprehensive network of specialty pharmacies.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CG3:GR €103.53 EUR +2.38

CG3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $72.81 USD -0.64
Biogen Idec Inc $290.54 USD -0.94
Eisai Co Ltd ¥3,931 JPY -10.00
Regeneron Pharmaceuticals Inc $296.74 USD -3.40
Shire PLC 2,925 GBp +25.00
View Industry Companies

Industry Analysis


Industry Average

Valuation CG3 Industry Range
Price/Earnings 42.0x
Price/Sales 9.0x
Price/Book 10.4x
Price/Cash Flow 33.5x
TEV/Sales 7.2x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at